



# Cambodia

Western Pacific Region




## I. Epidemiological profile

Population (UN)	2015	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	7,500,000	48	Plasmodium species: <i>P. falciparum</i> (61%), <i>P. vivax</i> (39%)
Low transmission (0-1 cases per 1000 population)	3,520,000	23	Major anopheles species: <i>An. dirus</i> , <i>An. minimus</i> , <i>An. maculatus</i> , <i>An. sundaicus</i>
Malaria-free (0 cases)	4,560,000	29	Reported confirmed cases (health facility): 33,930 Estimated cases: 120,000 [95,000 ; 150,000]
Total	15,580,000		Confirmed cases at community level: 16,370 Reported deaths: 10 Estimated deaths: 120 [17 ; 200]


## II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2000	First-line treatment of unconfirmed malaria	-	-					
	ITNs/ LLINs distributed to all age groups	Yes	2000	First-line treatment of <i>P. falciparum</i>	AS+MQ; DHA-PPQ+PQ	2000					
IRS	IRS is recommended	Yes	-	Treatment failure of <i>P. falciparum</i>	QN+T	2000					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AM; AS; QN	-					
Larval control	Use of larval control recommended	No	-	Treatment of <i>P. vivax</i>	DHA-PPQ	2011					
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2000	Type of RDT used	P.f + P.v specific (Combo)						
	Malaria diagnosis is free of charge in the public sector	Yes	2000								
Treatment	ACT is free of charge for all ages in public sector	Yes	2000	<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Is banned	2008	Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	2014	AS+MQ	2005-2016	0	1.4	19.4	42 days	17	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	2013	DHA-PPQ	2008-2016	0	8.3	62.5	42 days	30	<i>P. falciparum</i>
	G6PD test is a requirement before treatment with primaquine	Yes	2012	DHA-PPQ	2010-2016	0	0	3.3	28 days	8	<i>P. vivax</i>
	Directly observed treatment with primaquine is undertaken	No	-								
	System for monitoring adverse reactions to antimalarials exists	No	2010								
Surveillance	ACD for case investigation (reactive)	No	-	<b>Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)</b>							
	ACD of febrile cases at community level (pro-active)	No	-	Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested		
	Mass screening is undertaken	Yes	2010	2014	Yes	Yes			An. dirus, An. minimus, other		
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	No	-									


## III. Financing




## Government expenditure by intervention in 2015




## IV. Coverage




## Cases tested and treated in public sector




## V. Impact



## Test positivity



## Confirmed malaria cases per 1000 and ABER



## Malaria admissions and deaths (per 100 000)

